Dabigatran-associate Acute Generalized Exanthematous Pustulosis (AGEP) in a psoriatic patients undergoing Ixekizumab and its pathogenetic mechanism

Dabigatran is a broad used new anticoagulant that recently was described to trigger pustular psoriasis. We describe a 49-year-old Caucasian male with psoriasis that after switching from warfarin to dabigatran developed acute generalised exanthematous pustulosis (AGEP). Remarkably we hypothesized a mechanism based increased lipid peroxidation via carboxilesterse-1. In conclusion, higher awareness should be used in patients with inflammatory skin manifestations that undergo new oral anticoagulants.